Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6764MR)

This product GTTS-WQ6764MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6764MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10999MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ9294MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ14888MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ11078MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ7496MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ5383MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ15440MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ12024MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW